19 cases spanning guideline-directed medical therapy, device timing, and drug selection across HFrEF and HFpEF.
A single patient, newly diagnosed with HFrEF on top of a lifetime of asthma. The disagreement isn't about whether she needs a beta-blocker — everyone agrees she does — it's about which one, how much to trust a quiet chest exam, and how fast to get her to target dose.
A single patient, four days into decompensated heart failure. The disagreement isn't about whether he needs more decongestion — it's about which second agent earns its risk in a kidney that was already running short before any of this started.
A single patient, thirty-six hours into an admission for decompensated heart failure. The textbook next step for inadequate diuresis is a second drug lower in the nephron — but that same drug is the one most likely to make an already-falling sodium worse.
Three days after an anterior STEMI, sacubitril/valsartan looks like the right next drug for his new low ejection fraction. The disagreement is whether his creatinine — still moving, not yet a settled number — is reliable enough yet to base today's decision on.
He qualifies for the drug his guidelines call the fourth pillar of his regimen, and the visit that could finally start it may be the best chance he gets. He also hasn't kept down half a meal tray in three days — the exact circumstance under which this drug has been linked to a rare, easy-to-miss complication.
His beta-blocker is not undertreated — it's genuinely maxed out, confirmed twice over. His resting heart rate still won't come down. The disagreement isn't about whether to add ivabradine; it's about how much of its trial evidence actually belongs to a patient like him.
He already tried the fourth medication in his heart-failure regimen once, and quietly stopped taking it himself without saying why. Restarting it means deciding whether to give him the same drug at a lower dose, or the costlier alternative built specifically to avoid the reason he stopped.
A single patient, clinically stable for eighteen months on a fully optimized ACE-inhibitor-based regimen, is offered a switch to sacubitril/valsartan on the strength of a real mortality benefit. He hears the actual numbers and says he'd rather stay on what he's already taking — the debate here is less about whether the drug works than about how many times a well-informed no should be revisited.
A single patient with heart failure with preserved ejection fraction needs an SGLT2 inhibitor added to her regimen — but empagliflozin and dapagliflozin don't share the same renal-function floor, and her own kidney function is moving toward the one threshold that actually separates them.
A single patient, two days into a pneumonia-triggered decompensation of her chronic heart failure, whose fever should be raising her heart rate and isn't — because the same beta-blocker she has taken since her heart attack may also be blunting the compensatory response that would otherwise reveal whether her kidneys and hands are underperfused.
A patient with heart failure has improved on three of the four guideline-recommended drug classes. The fourth — a mineralocorticoid receptor antagonist — carries its own proven mortality benefit, but today's labs sit close enough to the thresholds used to screen it out that starting it is no longer a simple next step.
A newly diagnosed heart failure patient's ejection fraction has climbed from twenty percent to thirty-three over twelve weeks of drug therapy — real improvement, but still below the threshold guidelines use to reconsider a defibrillator. The disagreement isn't whether to keep adjusting his medications. It's whether three separate dose-limiting events already mean he's reached his ceiling, or whether concluding that this early would be premature.
Four guideline-recommended drug classes, no mandated starting order — sequencing comes down to each patient's own risk profile.
New HFrEF and stable moderate COPD, already on three of the four GDMT pillars. The beta-blocker decision turns out to rest less on a settled mortality comparison than most of the group assumed going in.
Reliable diuresis every time he's hospitalized on IV furosemide, and genuinely unpredictable diuresis on the same oral dose at home. The bioavailability argument for switching drugs fits his pattern precisely — the largest trial on the question found no difference at all.
Persistent HFrEF symptoms on fully optimized quadruple GDMT. The next guideline-recommended add-on has a real mortality benefit behind it — proven in a population, and by a pathway, that don't technically describe this patient.
Stable ambulatory HFrEF, no clinical signs of decompensation, but a biomarker that has climbed across three consecutive visits. The largest trial built to answer whether that trend should trigger treatment found, unambiguously, that it shouldn't drive the decision alone.
Left bundle branch block, EF 30%, and a QRS duration reading two milliseconds short of the guideline's Class I threshold for cardiac resynchronization. His GDMT is also still mid-titration — two real reasons the decision isn't as simple as reading the number off the ECG.
An ejection fraction of 48% sits well inside the exact subgroup where the pivotal HFpEF trial found its clearest benefit — even though the trial's own headline result missed statistical significance by a narrow margin.